Delayed Minimally Invasive Injection of Allogenic Bone Marrow Stromal Cell Sheets Regenerates Large Bone Defects in an Ovine Preclinical Animal Model

• DOI: 10.5966/sctm.2014-0244
• Publication Date: 2015-04-02T14:40:42Z
• Authors: Arne Berner; Jan Henkel; Maria A. Woodruff; Roland Steck; Michael Nerlich; Michael A. Schuetz; Dietmar W. Hutmacher
• Keywords: 0301 basic medicine; Bone Regeneration; Sheep; Bone Marrow Cells; Mesenchymal Stem Cells; Allogenic; Mesenchymal Stem Cell Transplantation; Bone regeneration; Bone tissue engineering; 3. Good health; 03 medical and health sciences; Cell injection; Models, Animal; Large bone defect; Mesenchymal stem cells; Animals; Humans; Transplantation, Homologous; Stromal Cells

Abstract Cell-based tissue engineering approaches are promising strategies in the field of regenerative medicine. However, mode cell delivery is still a concern and needs to be significantly improved. Scaffolds and/or matrices loaded with cells often transplanted into bone defect immediately after has been created. At this point, nutrient oxygen supply low inflammatory cascade incited, thus creating highly unfavorable microenvironment for survive participate regeneration process. We therefore developed unique treatment concept using delayed injection allogenic marrow stromal (BMSC) sheets regenerate critical-sized tibial sheep study effect cells' potential when introduced at postinflammatory stage. Minimally invasive percutaneous BMSCs biodegradable composite scaffolds 4 weeks surgery led improved compared preseeded scaffold/cell constructs scaffold-only groups. Biomechanical testing microcomputed tomography showed comparable results clinical reference standard (i.e., an autologous graft). To our knowledge, we first show validated preclinical large animal model that transplantation can provide applicable alternatives challenging defects future. Significance From translational point view, comprehensive presented, which scaffold those gold standard, namely autograft. authors' display could